Car-T Cell Therapy: Genetic Engineering and Modern Approaches in Treating Blood Cancer
Downloads
Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a paradigm shift in oncology, transforming patient care from conventional chemical interventions into highly precise, personalized cellular immunotherapy. Often described as a "living drug," CAR-T cell therapy involves the extraction and genetic modification of a patient’s own T-lymphocytes to express receptors targeted specifically against malignant surface proteins. This article explores the sophisticated manufacturing pipeline of CAR-T cells, evaluates their clinical efficacy in treating hematological malignancies such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), addresses the management of severe systemic toxicities, and discusses the future horizons of off-the-shelf allogeneic cell products.
[1] D. W. Lee, B. D. Santomasso, F. L. Locke, and others, ‘ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells’, Biology of Blood and Marrow Transplantation, vol. 25, no. 4, pp. 625–638, 2019.
[2] F. L. Locke, D. B. Miklos, C. A. Jacobson, and others, ‘Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma’, New England Journal of Medicine, vol. 386, no. 7, pp. 640–654, 2022.
[3] S. S. Neelapu, F. L. Locke, N. L. Bartlett, and others, ‘Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma’, New England Journal of Medicine, vol. 377, no. 26, pp. 2531–2544, 2017.
[4] C. H. June and M. Sadelain, ‘Chimeric antigen receptor therapy’, New England Journal of Medicine, vol. 379, no. 1, pp. 64–73, 2018.
[5] D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, and C. H. June, ‘Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia’, New England Journal of Medicine, vol. 365, no. 8, pp. 725–733, 2011.
[6] P. Jacquet and P. H. Sugarbaker, ‘Clinical research methodologies in diagnosis and management of patients with peritoneal carcinomatosis’, in Cancer Treatment and Research, vol. 82, 1996, pp. 359–374.
[7] D. Sulaymonov and I. Sodiqov, ‘Comparative evaluation of the diagnostic accuracy of CT and MRI in the detection of liver metastases’, South Aral Region Medical Journal, vol. 2, no. Special Issue 2, pp. 514–520, 2026.
[8] N. C. Munshi, L. D. Anderson, N. Shah, and others, ‘Idecabtagene vicleucel in relapsed and refractory multiple myeloma’, New England Journal of Medicine, vol. 384, no. 8, pp. 705–716, 2021.
[9] Silk Way TV, ‘Kazakh blood cancer drug testing to begin in 2026’. [Online]. Available: https://silkwaytv.kz/en/kazakh-blood-cancer-drug-testing-to-begin-in-2026_55552
[10] Uzbekistan National News Agency (UzA), ‘Learning from Singapore’s experience’. [Online]. Available: https://uza.uz/en/posts/learning-from-singapores-experience_696758
[11] N. N. Shah and T. J. Fry, ‘Mechanisms of resistance to CAR T cell therapy’, Nature Reviews Clinical Oncology, vol. 16, no. 6, pp. 372–385, 2019.
[12] W. Qasim, H. Zhan, S. Samarasinghe, and others, ‘Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells’, Science Translational Medicine, vol. 9, no. 374, 2017.
[13] GxP News, ‘New approaches to using the potential of CAR-T therapy’. Apr. 2026. [Online]. Available: https://gxpnews.net/2026/04/novye-podhody-v-ispolzovanii-vozmozhnostej-car-t-terapii/
[14] O. Glehen, F. Mohamed, and F. N. Gilly, ‘Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia’, The Lancet Oncology, vol. 5, no. 4, pp. 219–228, 2004.
[15] D. Elias, F. Gilly, F. Boutitie, and others, ‘Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study’, Journal of Clinical Oncology, vol. 28, no. 1, pp. 63–68, 2010.
[16] V. J. Verwaal, S. van Ruth, E. de Bree, and others, ‘Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in colorectal cancer patients with peritoneal carcinomatosis’, Journal of Clinical Oncology, vol. 21, no. 20, pp. 3737–3743, 2003.
[17] J. Eyquem, J. Mansilla-Soto, T. Giavridis, and others, ‘Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection’, Nature, vol. 543, no. 7643, pp. 113–118, 2017.
[18] M. Sadelain, R. Brentjens, and I. Rivière, ‘The basic principles of chimeric antigen receptor design’, Cancer Discovery, vol. 3, no. 4, pp. 388–398, 2013.
[19] S. J. Schuster, M. R. Bishop, C. S. Tam, and others, ‘Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma’, New England Journal of Medicine, vol. 380, no. 1, pp. 45–56, 2019.
[20] J. N. Kochenderfer and S. A. Rosenberg, ‘Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors’, Nature Reviews Clinical Oncology, vol. 10, no. 5, pp. 267–276, 2013.
[21] M. Chmielewski and H. Abken, ‘TRUCKs: the fourth generation of CARs’, Expert Opinion on Biological Therapy, vol. 15, no. 8, pp. 1145–1154, 2015.

